drugset / Trial / NCT00290927

Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus

NCT00290927 ↗

Phase 3 Completed 390 enrolled Sanofi
RandomizedParallel-groupOpen-labelTreatment

Summary

* To evaluate the superiority in the efficacy of HMR1964 and OHA combination therapy as compared with OHA therapy. * To evaluate the superiority in the efficacy of HMR1964 mono-therapy as compared with OHA therapy. * To evaluate the safety of HMR1964.

Timeline

Start
2003-12
Primary completion
—
Completion
—

Outcome

Met primary endpoint

paper Superiority of glulisine + OAD and glulisine monotherapy vs. OAD only was shown by differences in adjusted mean HbA(1c) change from baseline values of -1.46% (p < 0.0001) and -0.64% (p < 0.0001) respectively. PMID 19614946 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin glulisine Protein / enzyme biologic 0.2 iu/kg Subcutaneous